Old versus new gene therapy for globin disorders.
作者信息
Herzog Roland W, Bungert Jörg
机构信息
Department of Pediatrics, Gene and Cell Therapy Program, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Department of Biochemistry and Molecular Biology, Center for Epigenetics, Genetics Institute, UF Health Cancer Center, Powell-Gene Therapy Center, Gainesville, FL 32610, USA.
出版信息
Mol Ther. 2021 Jun 2;29(6):1933-1934. doi: 10.1016/j.ymthe.2021.04.031. Epub 2021 May 7.
Abstract
摘要
相似文献
1
Old versus new gene therapy for globin disorders.用于珠蛋白生成障碍性贫血的新旧基因疗法
Mol Ther. 2021 Jun 2;29(6):1933-1934. doi: 10.1016/j.ymthe.2021.04.031. Epub 2021 May 7.
2
[Globin gene induction therapy for β-thalassemia].[β地中海贫血的珠蛋白基因诱导疗法]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):237-40. doi: 10.7534/j.issn.1009-2137.2014.01.047.
3
Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy.重度β地中海贫血患者的治疗选择：珠蛋白基因治疗的必要性。
Hum Gene Ther. 2007 Jan;18(1):1-9. doi: 10.1089/hum.2006.151.
4
Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.使用慢病毒载体成功矫正人类重型β地中海贫血表型。
Blood. 2004 Dec 1;104(12):3445-53. doi: 10.1182/blood-2004-04-1427. Epub 2004 Aug 3.
5
Reversal of lethal alpha- and beta-thalassemias in mice by expression of human embryonic globins.通过表达人类胚胎球蛋白逆转小鼠致死性α和β地中海贫血。
Blood. 1998 Nov 1;92(9):3057-63.
6
Expression of beta-globin in primary erythroid progenitors of beta-thalassemia patients using an SV40-based gene delivery system.使用基于SV40的基因递送系统在β地中海贫血患者的原代红系祖细胞中表达β-珠蛋白。
J Hematother Stem Cell Res. 1999 Dec;8(6):593-9. doi: 10.1089/152581699319759.
7
The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.慢病毒介导的人γ-珠蛋白基因转移后，中间型小鼠β地中海贫血的表型校正程度受染色体位置效应和载体拷贝数的影响。
Blood. 2003 Mar 15;101(6):2175-83. doi: 10.1182/blood-2002-07-2211. Epub 2002 Oct 31.
8
Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.使用侧翼带有鸡高敏位点4染色质绝缘子的慢病毒载体成功矫正人类重型库利贫血（β-地中海贫血）主要表型。
Ann N Y Acad Sci. 2005;1054:238-49. doi: 10.1196/annals.1345.030.
9
Thalassemia intermedia due to a novel mutation in the second intervening sequence of the beta-globin gene.由于β-珠蛋白基因第二个间隔序列中的新突变导致的中间型地中海贫血。
Hemoglobin. 2007;31(4):433-8. doi: 10.1080/03630260701613210.
10
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.一种新型的库利贫血小鼠模型及其通过慢病毒介导的人β-珠蛋白基因转移的挽救。
Blood. 2003 Apr 15;101(8):2932-9. doi: 10.1182/blood-2002-10-3305. Epub 2002 Dec 12.
本文引用的文献
1
Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral gene therapy vector for β-thalassemia.多顺反子慢病毒基因治疗载体中β-珠蛋白的协调表达和α2-珠蛋白的降低用于β-地中海贫血。
Mol Ther. 2021 Sep 1;29(9):2841-2853. doi: 10.1016/j.ymthe.2021.04.037. Epub 2021 May 1.
2
A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease.基因治疗的停顿：反思镰状细胞病的独特挑战
Mol Ther. 2021 Apr 7;29(4):1355-1356. doi: 10.1016/j.ymthe.2021.03.010. Epub 2021 Mar 19.
3
Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies.慢病毒载体 ALS20 可实现高血红蛋白水平和低基因组整合，用于治疗β-地中海贫血症。
Mol Ther. 2021 Apr 7;29(4):1625-1638. doi: 10.1016/j.ymthe.2020.12.036. Epub 2021 Jan 29.
4
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.CRISPR-Cas9 基因编辑治疗镰状细胞病和 β-地中海贫血。
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
Zotero 插件